Literature DB >> 9990134

Identification of trimeric myosin phosphatase (PP1M) as a target for a novel PKC-potentiated protein phosphatase-1 inhibitory protein (CPI17) in porcine aorta smooth muscle.

S Senba1, M Eto, M Yazawa.   

Abstract

CPI17, a phosphorylation-dependent inhibitory protein of protein phosphatase-1 (PP1), is dominantly expressed in smooth muscle, and the inhibitory activity is potentiated by protein kinase C and its related enzymes [Eto, M. et al. (1997) FEBS Lett. 410, 356-360]. In order to identify its physiological target in smooth muscle, the myofibrillar extract from porcine aorta media was analyzed by affinity chromatography on CPI17-conjugated Sepharose. The binding of phosphatases to the resin depended on thiophosphorylation of CPI17, and about 90% of the phosphatase activities toward phosphorylated myosin (p-myosin) and phosphorylase-a were bound to the resin and could be eluted with 0.5 M NaCl. The IC50 values of thiophosphorylated CPI17 toward phosphatases bound to the resin were in the range of 0.5-3 nM, as expected for the PP1 holoenzymes sensitive to CPI17. The CPI17-sensitive fraction was further separated into several peaks of phosphatase activity by column chromatography on Mono Q, which suggested multiple functions of CPI17 as a mediator of the protein kinase C-related signal transduction pathway in aorta smooth muscle. The major activity toward p-myosin was identified as the myofibril-bound PP1 (PP1M), and its subunit composition (140, 37, and 20 kDa) was consistent with that of PP1M from chicken gizzard and porcine bladder. The purified PP1M was completely inhibited by phosphorylated and thiophosphorylated CPI17. Kinetic analysis showed mixed inhibition of PP1M by CPI17 (Ki = 1.9 nM and Ki' = 5.1 nM). The concentration of CPI17 in aorta smooth muscle cells was estimated to be at least 0. 3 microM from the result of Western analysis. This concentration appears to be sufficient to suppress the in situ PP1M in aorta smooth muscle, and PP1M is thus identified as a target of CPI17 in vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990134     DOI: 10.1093/oxfordjournals.jbchem.a022294

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  29 in total

Review 1.  Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.

Authors:  A P Somlyo; A V Somlyo
Journal:  J Physiol       Date:  2000-01-15       Impact factor: 5.182

2.  Expression of CPI-17 and myosin phosphatase correlates with Ca(2+) sensitivity of protein kinase C-induced contraction in rabbit smooth muscle.

Authors:  T P Woodsome; M Eto; A Everett; D L Brautigan; T Kitazawa
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

3.  Cholangiocyte myosin IIB is required for localized aggregation of sodium glucose cotransporter 1 to sites of Cryptosporidium parvum cellular invasion and facilitates parasite internalization.

Authors:  Steven P O'Hara; Gabriella B Gajdos; Christy E Trussoni; Patrick L Splinter; Nicholas F LaRusso
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

4.  Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists.

Authors:  Winnie W C Shum; Geng-Yun Le; Robert L Jones; Alison M Gurney; Yasuharu Sasaki
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

5.  Reciprocal regulation controlling the expression of CPI-17, a specific inhibitor protein for the myosin light chain phosphatase in vascular smooth muscle cells.

Authors:  Jee In Kim; Mark Urban; Garbo D Young; Masumi Eto
Journal:  Am J Physiol Cell Physiol       Date:  2012-04-25       Impact factor: 4.249

6.  Phosphorylation-induced conformational switching of CPI-17 produces a potent myosin phosphatase inhibitor.

Authors:  Masumi Eto; Toshio Kitazawa; Fumiko Matsuzawa; Sei-Ichi Aikawa; Jason A Kirkbride; Noriyoshi Isozumi; Yumi Nishimura; David L Brautigan; Shin-Ya Ohki
Journal:  Structure       Date:  2007-12       Impact factor: 5.006

Review 7.  Intestinal dysmotility in inflammatory bowel disease: mechanisms of the reduced activity of smooth muscle contraction.

Authors:  Hiroshi Ozaki; Masatoshi Hori; Kazuya Kinoshita; Takashi Ohama
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

8.  Juxtamembrane localization of the protein phosphatase-1 inhibitor protein PHI-1 in smooth muscle cells.

Authors:  Nikolaos A Tountas; James W Mandell; Allen D Everett; David L Brautigan
Journal:  Histochem Cell Biol       Date:  2004-04-09       Impact factor: 4.304

9.  Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway.

Authors:  Karnam S Murthy; Huiping Zhou; John R Grider; David L Brautigan; Masumi Eto; Gabriel M Makhlouf
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

10.  Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase.

Authors:  Jing Ti Deng; Cindy Sutherland; David L Brautigan; Masumi Eto; Michael P Walsh
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.